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A B S T R A C T
With ageing of the global society, the frequency of ageing-related neurodegenerative diseases such as
Alzheimer`s disease (AD) is on the rise worldwide. Currently, there is no cure for AD, and the four drugs ap-
proved for AD only have very small effects on AD symptoms. Consequently, there are enormous efforts
worldwide to identify new targets for treatment of AD. Approaches that interfere with classical neuropathologic
features of AD, such as extracellular senile plaques formed of aggregated amyloid-beta (Abeta), and intracellular
neurofibrillary tangles of hyperphosphorylated tau have not been successful so far. In search for a treatment
approach of AD, we found that inhibition of the angiotensin-converting enzyme (ACE) by a centrally acting ACE
inhibitor retards symptoms of neurodegeneration, Abeta plaque formation and tau hyperphosphorylation in
experimental models of AD. Our approach is currently being investigated in a clinical setting. Initial evidence
with AD patients shows that a brain-penetrating ACE inhibitor counteracts the process of neurodegeneration and
dementia. Moreover, centrally acting ACE inhibitors given in addition to the standard therapy, cholinesterase
inhibition, can improve cognitive function of AD patients for several months. This is one of the most promising
results for AD treatment since more than a decade.
1. Introduction
Alzheimer`s disease (AD) is the most frequent form of dementia, and
with increasing age of the global society on the rise worldwide [1].
Currently, there are only four drugs approved for the treatment of AD:
three cholinesterase inhibitors, and the NMDA (N-methyl-D-aspartate)
glutamate receptor antagonist, memantine [2]. All these drugs alleviate
symptoms of dementia for only a few months but cannot halt disease
progression [2]. Thus, there is an urgent need for new drugs to improve
therapy of AD.
Research on pathomechanisms identified major neuropathologic
features in brains of AD patients, which are characterized by extra-
cellular plaques of aggregated amyloid-beta (Abeta), and intracellular
neurofibrillary tangles formed of hyperphosphorylated PHF (paired
helical filament) tau [3]. Impaired clearance and/or enhanced
generation of aggregation-prone amyloid-beta, Abeta oligomers and
formation of Abeta plaques are considered to be hallmarks of the aging-
induced process of neurodegeneration while neurofibrillary tangles of
hyperphosphorylated tau could form as a consequence of aberrant
Abeta accumulation [4–6]. According to this amyloid hypothesis of AD,
Abeta is the major pathologic driver, which triggers the disease [6].
This conclusion is supported by several lines of evidence, which es-
tablished the disease relevance of Abeta. Mutations in the amyloid-beta
region of the amyloid precursor protein (APP) are associated with fa-
milial Alzheimer`s disease, FAD [7]. Transgenic animal models with
neuron-specific expression of FAD-associated APP mutants reproduce
major AD symptoms such as cognitive impairment, neurodegeneration
and accumulation of Abeta plaques with increasing age [8,9]. In recent
years, the amyloid hypothesis of AD was complemented by evidence,
which also supports a major role of PHF tau in AD pathogenesis. In
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transgenic mice, a dementia-associated tau mutant strongly accelerated
disease progression induced by brain-specific expression of an FAD-
related mutant of APP [10,11]. In patients, the content of hyperpho-
sphorylated PHF tau correlates with neuronal loss in AD brains [5].
Based on these data, it was concluded that aggregated Abeta and hy-
perphosphorylated PHF tau synergistically enhance the irreversible
neurodegenerative process and dementia in AD [12–14].
Because of the causal involvement in disease symptoms of experi-
mental AD models, treatment approaches were developed, which in-
terfere with Abeta production and/or enhance Abeta clearance and
degradation [15–21]. One of the most promising approaches targets the
formation of Abeta plaques by Abeta-specific antibodies. But this con-
cept is currently under discussion because all major clinical trials with
Abeta-targeting antibodies did not show any improvement of disease
symptoms, notably dementia [15–18]. Moreover, active immunization
against Abeta could induce severe neurological side effects and me-
ningoencephalitis [19]. In addition, inhibition of Abeta generation by a
small molecule inhibitor of the rate-limiting Abeta-generating enzyme,
beta-secretase (BACE), also was ineffective in AD patients in a phase III
clinical trial and had severe side effects [20,21]. In view of these dis-
appointing results, it is questioned whether Abeta is the right target
[22]. Instead, inhibition of PHF tau accumulation is the focus of several
experimental and clinical trials with tau-specific antibodies [23,24].
Outcome data of these clinical trials currently are not available. Taken
together, development of a successful treatment strategy for AD cur-
rently is not feasible because the right target is lacking.
In search for a possible target for AD treatment, we focussed on the
neuronal angiotensin system because several components of this system
are altered in AD brains. Notably, neuronal levels of the angiotensin II-
generating angiotensin-converting enzyme, ACE, are increased in brains
of AD patients [25–27]. By stimulation of the type-1 angiotensin II re-
ceptor (AT1 receptor) encoded by the type-1 angiotensin II receptor
gene (AGTR1), ACE-generated angiotensin II is known to promote
neurodegeneration and brain ageing [28,29]. On the other hand, it was
found that ACE could be an Abeta-degrading enzyme [30]. From these
in vitro data, it was discussed that inhibition of ACE could aggravate AD
symptoms by increasing the accumulation of Abeta [30]. However, in
vivo studies did not show an enhanced Abeta generation upon genetic
inactivation of ACE or ACE inhibition [31]. In addition, so far, all
Abeta-targeting approaches failed to improve AD symptoms in larger
cohorts of patients [15–22].
Therefore, we focussed on ACE inhibition as a potential neuropro-
tective approach and analysed the impact of ACE inhibition on symp-
toms of AD in different experimental AD models. We found that ACE
inhibition with a brain-penetrating ACE inhibitor, captopril, retarded
major AD symptoms, and triggered a neuro-regenerative gene expres-
sion signature in AD mice [32,33]. Notably, ACE inhibition prevented
the AD-related decreases in transcript levels of 38 hippocampal genes
with established functions in neuronal regeneration and cognition [32].
Captopril not only retarded AD-related hippocampal neurodegenera-
tion, but also actively promoted hippocampal neuro-regeneration. Ac-
tive neuro-regeneration by captopril was documented by up-regulation
of transcript levels of 12 hippocampal genes encoding neuronal struc-
ture-forming proteins above the levels of the young control group [32].
ACE-inhibition-induced hippocampal neuro-regeneration was further
confirmed by immuno-fluorescence detection of hippocampal Epha4,
the Ephrin type-A receptor 4, which is reduced in hippocampal biopsy
specimens from AD mice and AD patients before the onset of memory
decline [32,34]. Immuno-fluorescence microscopy documented that six
months of captopril treatment had promoted the regeneration of Epha4-
positive CA1 neuronal processes of aged 18-month-old Tg-2576 AD
mice, which were substantially degenerated not only in 18-month-old
AD mice but also in 12-month-old AD mice [32]. Other experimental
data complement these findings and show that central ACE inhibition-
mediated neuroprotection could be attributed to suppression of pro-
inflammatory microglia and astrocyte activation, and attenuation of
oxidative stress [35]. This neuroprotective activity of central ACE in-
hibition, which is deduced from our and other experimental studies, is
supported by recent clinical data, which document beneficial neuro-
protective activity of brain-penetrating ACE inhibitors [36].
2. ACE is a key component of the peripheral and neuronal renin-
angiotensin-aldosterone system, RAAS
The physiologic and pathophysiologic functions of the angiotensin-
converting enzyme, ACE, are well-established [28]. By generation of
angiotensin II, ACE is the key component of the renin-angiotensin-al-
dosterone system, RAAS (Fig. 1).
ACE generates angiotensin II from its precursor angiotensin I, which
is derived from renin-mediated cleavage of angiotensinogen.
Fig. 1. Overview of major physiologic and pathophysiologic
functions of peripheral and central ACE, and the AT1 receptor,
which can be targeted by approved drugs. Components of the
angiotensin system, which counteract functions of ACE and the
AT1 receptor are coloured in green (For interpretation of the re-
ferences to colour in this figure legend, the reader is referred to the
web version of this article).
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Angiotensin II exerts major physiologic and pathophysiologic functions
by activating the angiotensin II AT1 receptor protein, which is encoded
in humans by AGTR1 (Fig. 1). Target organs of angiotensin II are the
kidney, the heart and the vasculature. In the kidney, the AT1 receptor
controls salt and water homeostasis, in part by stimulating the forma-
tion of aldosterone. In the heart, enhanced AT1 receptor activation
promotes cardiac remodelling and aggravates the progression of heart
failure. In the vasculature, AT1 stimulates vascular contraction and the
synthetic vascular smooth muscle phenotype, and thereby contributes
to the pathophysiology of hypertension, and atherosclerosis [28,37].
Based on these important pathophysiologic processes, inhibition of
angiotensin II generation by an ACE inhibitor is currently one of the
most important treatment approaches for hypertension, ischemic heart
disease and heart failure (Fig. 1).
In addition to the peripheral angiotensin system, all components of
the RAAS are also found in brain [38,39]. Activation of the sympathetic
nervous system is considered as one of the major functions of brain
RAAS [40]. Furthermore, central nervous system ACE could be a con-
tributing factor to hypertension and stroke [41,42]. By angiotensin II
AT1 receptor-stimulated generation of reactive oxygen species (ROS),
central nervous system ACE exerts neurodegenerative activity [35,43].
Apart from these functions, neuronal ACE and angiotensin II are in-
creasingly recognized for their involvement in neuropsychiatric and
neurodegenerative disorders such as depression, anxiety, mood dis-
orders, dementia, Parkinson`s disease and Alzheimer`s disease
[36,44–48].
Our review is focused on components of the angiotensin system,
which are targets of approved classes of antihypertensive drugs, i.e.
ACE and the angiotensin II AT1 receptor (Fig. 1). Functions of ACE and
the AT1 receptor are interconnected with other components of the
angiotensin-system, which currently cannot be targeted by approved
drugs directly. For instance, detrimental functions of ACE as the major
angiotensin II-generating enzyme, are counteracted by the angiotensin
II-degrading enzyme, ACE2, not only in the periphery but also in brain
[49]. In agreement with this notion, deficiency of ACE2, in ACE2
knockout mice, causes cognitive impairment [49]. The underlying
mechanism involves increased reactive oxygen species (ROS) genera-
tion, most likely by unrestrained activation of the AT1 receptor as a
consequence of exaggerated angiotensin II levels [49]. ACE2 inactivates
angiotensin II to generate angiotensin 1–7, which can exert in-
dependent vasodilatory effects, mainly by activation of MAS1 [50,51].
Upon inhibition of ACE, beneficial ACE2-dependent angiotensin 1–7
generation is enhanced, and this activity distinguishes ACE inhibitors
from AT1 antagonists [52]. Another component of the angiotensin
system is the angiotensin II AT2 receptor (AGTR2). The AT2 receptor
antagonizes functions of the AT1 receptor [53], and activation of the
AT2 receptor by angiotensin II is enhanced under conditions when the
AT1 receptor is blocked by an AT1-specific antagonist [54]. In addition
to beneficial actions of the AT2 receptor in peripheral organs, the AT2
receptor exerts neuroprotection and promotes neuronal regeneration
[55,56].
Taken together, detrimental neurodegenerative functions of ACE
and the AT1 receptor are counteracted by other components of the
angiotensin system, i.e. ACE2, MAS1 and the AT2 receptor.
Fig. 2. Immunohistological localization of ACE in aged AD mice. A, Immunofluorescence analysis localized ACE (green) and Abeta (red) in hippocampal vessels and
neurons of aged 18-month-old Tg2576 AD mice without (left) and with ACE inhibition (ACEI) with captopril (right); bar: 25 μm. B, Detection of neuronal ACE on
hippocampal CA1 neurons by immunohistology with anti-ACE antibodies; bar: 25 μm. Cell nuclei were stained with DAPI (A) and hematoxylin (HE; B). Images were
adapted from [32] (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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Consequently, strengthening of this “good” side of the angiotensin
system needs to be considered when beneficial therapeutic effects of
ACE inhibitors and AT1 receptor antagonists are evaluated, regarding
the treatment of cardiovascular disease and central nervous system
disorders.
3. ACE protein and activity are increased in brains from AD
patients and experimental AD models
A potential role of ACE in the pathogenesis of AD is discussed for
several decades. Major evidence came from histopathologic studies,
which found that the ACE protein is increased in brains from AD pa-
tients [25–27]. We also found an increased hippocampal ACE protein
and activity in the experimental AD model of Tg2576 mice [32], which
recapitulates features of FAD by neuron-specific expression of APPSwe,
i.e. the human amyloid precursor protein, APP695, containing the
double mutation K670 N, M671 L, which was identified in a Swedish
family with FAD [8]. Immunohistology localized the ACE protein in
brain vessels of aged Tg2576 AD mouse brains (Fig. 2A; and [32]). In
agreement with AD patients [27], vascular ACE was localized in brains
of Tg2576 AD mice in close proximity to vascular Abeta plaque deposits
(Fig. 2A; and [32]). ACE was found on the perivascular side in close
proximity to basal lamina whereas vascular Abeta deposits were facing
the vessel lumen indicative of cerebral amyloid angiopathy (Fig. 2A;
and [32]). Again, this finding is complementary to the localization of
ACE in brains of AD patients [27]. In addition, ACE and Abeta were
localized on hippocampal neurons and neuronal processes (Fig. 2A,B;
and cf. Fig. 3). This phenotype of Tg2576 AD mice recapitulates major
features of brains from AD patients [26,27]. In the Tg2576 AD model,
treatment with the ACE inhibitor, captopril, led to a decrease in vas-
cular Abeta accumulation (Fig. 2A; and [32]). In addition, treatment
with the ACE inhibitor, captopril, for six months counteracted the AD-
related increase in hippocampal ACE (Fig. 2B; and [32]).
In view of the increased ACE protein and activity in AD brains, a
pathophysiologic role of ACE in AD and neurodegeneration is under
investigation for more than 20 years. Initially, the increased ACE ac-
tivity in AD brains was discussed to promote degradation of Abeta in
vivo because ACE has measurable Abeta-degrading activity in vitro
[30]. In contrast to the in vitro situation with abundant amounts of
enzyme and substrate, in vivo data did not show a significant de-
gradation of Abeta peptides by ACE [31,57]. Moreover, ACE inhibition
with an ACE inhibitor did not lead to an increased Abeta accumulation
in vivo [57,58]. Instead, central ACE inhibition retarded AD pathology
in brains of AD animal models [32,58–60]. Notably, treatment with
different brain-penetrating ACE inhibitors, e.g. perindopril and capto-
pril, decreased Abeta plaque load and/or Abeta levels [32,58–60]. In
similar experiments, the Abeta-degrading activity of other vasopepti-
dases such as neprilysin (neutral endopeptidase, NEP), and endothelin-
converting enzyme was documented in vitro and in vivo, and also in AD
animal models [31,61–64].
In summary, the dominant function of ACE in vivo is the generation
of angiotensin II. By inhibition of angiotensin II peptide generation,
ACE inhibitors prevent the activation of the AT1 receptor, and ensuing
AT1 receptor inhibition is a sufficient cause for a decreased AD pa-
thology in various AD models and patients [65–69]. In vivo, the ben-
eficial AT1-inhibitory effect of ACE inhibitors apparently dominates
over other enzymatic activities of ACE, which can be measured in vitro
because in vivo, the endogenously expressed ACE does not significantly
degrade Abeta peptides [31,57]. Inefficient ACE-mediated cleavage of
Abeta peptides in vivo could - at least partially - be a consequence of
Abeta peptide phosphorylation at serine-8 [70]. Furthermore, AT1 re-
ceptor inhibition-independent modulation of other neuroprotective
targets of the angiotensin system, e.g. as a consequence of an increased
angiotensin 1–7 generation, could further contribute to the unique
neuroprotective profile of ACE inhibitors in vivo [52].
In this context, the role of the ACE I/D (insertion/deletion) poly-
morphism also was investigated. Individuals with the DD genotype
(homozygous for the deletion) have a two-fold increased serum ACE
activity [71]. Nevertheless, large meta-analyses did not find convincing
evidence of a major disease relevance of the ACE I/D polymorphism,
neither for cardiovascular disease nor AD symptoms and cognition
[72,73]. Other ACE variants, e.g. ACE variant rs4291, rs4343 and
rs1800764 also did not show a significant association with late-onset
AD in a large multi-centre study with ten Caucasian case-control po-
pulations [74]. In agreement with these data, a meta-analysis of all
publicly available datasets for genome-wide association studies
(GWAS), did not find a significant disease association between single
nucleotide polymorphisms (SNPs) of the ACE gene or any other com-
ponent of the renin-angiotensin-system and AD risk [75].
The largest genetic study on AD from the International Genomics of
Alzheimer`s Project, IGAP, with data from 35,274 AD cases with clin-
ical and autopsy-diagnosed AD and 59,163 controls confirmed that all
Fig. 3. Immunofluorescence localization of the AT1 receptor (green) and Abeta plaques (red) on hippocampal neurons of an aged Tg2576 AD mouse (bar: 25 μm).
Images were adapted from [32] (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
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previously investigated ACE variants did not show significant associa-
tion with LOAD risk, i.e. late-onset Alzheimer`s disease [76]. Instead,
the study suggested for non-Hispanic Whites a weak association be-
tween LOAD risk and a previously unrecognized rare SNP (MAF, minor
allele frequency: 0.02, i.e. 2%) in the ACE locus (rs138190086; ref
[76].). Because the study did not find any eQTLs (expression quanti-
tative trait loci) in close proximity to the newly identified AD-related
SNP [76], the impact of this SNP on ACE expression level is unknown.
GWAS loci are intergenic. Therefore, the actual risk gene is often dis-
tinct from the nearest annotated gene to the associated SNP. Thus, the
gene that is influenced by rs138190086 within the ACE locus could be
different from ACE and still awaits to be identified.
Taken together, this lacking (or weak) disease associations of ACE
polymorphisms with AD risk are most likely attributable to the fact that
genetic polymorphisms have minor impacts on risks of genetically
complex disorders such as cardiovascular disease and AD. Limitations
of the “pure” genetic approach eventually could be overcome by the
direct measurement of blood ACE and angiotensin II levels. In agree-
ment with this notion, data from a recent study showed a significant
association between elevated blood ACE, high angiotensin II levels, and
a worse cognitive function [77].
4. ACE inhibition counteracts major risk factors of AD by
inhibition of the AT1 receptor
By the increased generation of angiotensin II, the up-regulated ACE
protein in aged Tg-2576 AD mice could enhance major symptoms of
Alzheimer`s disease by activation of the AT1 receptor [65–68]. Notably,
genetic deficiency of the angiotensin II AT1a receptor in a transgenic
AD model, led to a significantly decreased Abeta plaque formation [66].
Likewise, a reduction in Abeta plaque load of AD mice was achieved by
treatment with different AT1 receptor antagonists [65,67,68]. In frame
of our immunohistological studies, we localized the AT1 receptor in
brains of aged Tg2576 AD mice. Immunohistology detected the angio-
tensin II AT1 receptor on hippocampal neurons of aged 18-month-old
Tg2576 mice (Fig. 3; and ref. [32]).
The AT1 receptor was localized in close proximity to insoluble
Abeta plaque deposits (Fig. 3; and [32]). Because an increased ACE
protein and activity were also found on hippocampal neurons (cf.
Fig. 2B; and [32]), the increased ACE-dependent angiotensin II gen-
eration in AD brain could directly enhance Abeta generation and
symptoms of neurodegeneration by AT1 receptor stimulation [65–69].
In agreement with this concept, inhibition of ACE with the brain-pe-
netrating, captopril, led to a significantly decreased Abeta plaque load
of aged Tg2576 AD mice [32].
Beneficial effects of angiotensin II AT1 receptor inhibition are well
documented regarding neuroprotection and slowing the progression of
AD [65–69]. ACE/AT1 receptor inhibition-mediated neuroprotection
was previously attributed to the attenuation of oxidative stress, and the
modulation of aberrant astroglial activation [35]. But do ACE inhibitors
and AT1 receptor antagonists interfere with the pathogenesis of Alz-
heimer`s disease directly? Pathomechanisms of AD initially were de-
duced from disease-causing mutations identified in cases of familial
Alzheimer`s disease, FAD, with autosomal-dominant inheritance of the
disease. Mutations were identified in the amyloid precursor protein,
APP, of early-onset FAD patients (i.e. patients with the autosomal
dominant-form of early-onset AD) and led to the amyloid hypothesis of
AD [6,7,78,79]. However, specific genetic changes, which ultimately
cause AD, are rare (less than 1%) and usually do not occur in patients
with late-onset sporadic AD, which encompass more than 95% of all AD
cases [79]. Therefore, the pathogenesis of late-onset sporadic AD could
have additional causes and risk factors. Search for pathomechanisms
led to the concept that late-onset sporadic AD is caused by a synergistic
interplay between genetic, environmental and lifestyle risk factors
[1,80]. Among different risk factors, the greatest risk factor of late-
onset sporadic AD is advanced age [1]. In addition to advanced age,
there are only a few other risk factors with well-established impact on
the pathogenesis of AD and vascular dementia, i.e. diabetes, smoking,
midlife hypertension, obesity, physical inactivity, depression, and low
educational level [80].
Considering advanced age and the other seven major risk factors of
AD, it is noteworthy to mention that ACE inhibitors and AT1 antago-
nists, target almost all of these major dementia-accelerating risk factors.
(I) Aging: Genetic and pharmacologic inhibition of ACE and/or the
AT1 receptor has direct anti-aging effects and leads to an extended
life span of experimental models [81–83].
(II) Diabetes type 2 and insulin resistance: Numerous studies show that
ACE and AT1 receptor inhibition ameliorate symptoms of diabetes
type 2 and improve insulin resistance [84–86]. Brains of AD pa-
tients are characterized by insulin resistance, and the metabolic
syndrome is associated with an enhanced Abeta plaque accumu-
lation [87,88]. Consequently, improvement of insulin resistance is
considered as an emerging new therapeutic target in AD [87], and
modulation of serum adipocytokines and glucose homeostasis is
considered to contribute to retardation of cognitive decline
achieved by ACE inhibitors and angiotensin II AT1 receptor an-
tagonists [89]. The antidiabetic activity of ACE inhibitors seems
even stronger compared to AT1 antagonists and involves AT1 re-
ceptor inhibition-dependent and independent effects [90,91].
(III) Obesity: Genetic deficiency and inhibition of ACE and other
components of the angiotensin system document that ACE in-
hibition has direct anti-obesity effects [92–95]. The anti-obesity
effect of ACE inhibition could involve an increased abundance of
angiotensin 1–7, and this effect distinguishes ACE inhibitors from
AT1 antagonists [95].
(IV) High blood pressure: Midlife hypertension is a well-established
risk factor for dementia later in life, in part by deterioration of the
structure and function of cerebral blood vessels [96]. In addition,
experimental data in mice and pigs provide evidence for a causal
association of hypertension with enhanced AD pathology [97]. In
agreement with these data, a higher systolic blood pressure is not
only associated with an increased incidence of brain infarcts but
also with an increased AD pathology, specifically tau tangles [98].
Moreover, in patients with diagnosed AD, hypertension is asso-
ciated with worse cognitive function, behavioural symptoms and
hippocampal glucose hypometabolism [99]. Therefore, adequate
blood pressure control by ACE inhibitors and AT1 receptor an-
tagonists seems to act in synergy with other beneficial activities of
these drugs. Adequate blood pressure control is more important in
midlife and early old age (< 75 years) as the dementia risk asso-
ciated with increased systolic blood pressure declines in old age
[98,100].
(V) Depression: ACE inhibitors and AT1 receptor antagonists have
positive effects on symptoms of depression [46,101]. This anti-
depressant activity of ACE inhibitors and AT1 receptor antagonists
could account for the observed decreased risk of mood disorders in
patients treated with ACE inhibitors and AT1 antagonists com-
pared to other antihypertensive medications [45].
(VI) Cognition: Numerous lines of evidence provide strong evidence
that continuous angiotensin II stimulation impairs cognitive
function by stimulation of the AT1 receptor [102]. Impaired cog-
nitive function stimulated by angiotensin II involves a decrease in
cerebral blood flow, an increased oxidative stress, neuroin-
flammation and neuronal senescence [102]. A direct angiotensin II
AT1 receptor-stimulated effect on cognition involves inhibition of
the potassium-stimulated release of acetylcholine in rat and
human brain cortex [103,104]. Consequently, an ACE inhibitor-
mediated decrease in angiotensin II peptide levels could improve
cognition by increasing the cognition-enhancing acetylcholine
[105]. Numerous subsequent studies with experimental models
and patients support these early findings and show that inhibition
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of the ACE-AT1 receptor axis by ACE inhibitors and/or AT1 an-
tagonists leads to a better outcome regarding cognition and de-
mentia symptoms, partly independent of direct actions on brain
Abeta levels e.g. [34,106–116].
Despite this multifaceted activity, the beneficial profile of ACE in-
hibitors and AT1 receptor antagonists could eventually be overcome by
the strong influence of potent genetic risk factors of AD such as the
APOE epsilon4 allele and/or modulated by the ACE genotype
[117,118]. Nevertheless, centrally acting AT1 antagonists and ACE in-
hibitors target basically all of the major risk factors, which are known to
contribute to vascular dementia and AD.
5. Stress is a causative factor of ACE induction in Alzheimer`s
disease
We elucidated the cause of ACE up-regulation in Alzheimer`s dis-
ease. Our focus was the activation of the hypothalamic pituitary adre-
nocortical (HPA) axis with subsequently increased corticosteroid gen-
eration, which is a well-established trigger of ACE up-regulation
[119–121]. In agreement with the involvement of the HPA axis in ACE
induction, we found that chronic unpredictable mild stress (CUMS),
which mimics environmental stress as an important risk factor of AD,
promoted a strong induction of the hippocampal ACE protein and ac-
tivity [33]. This finding is relevant to the pathophysiology of AD in
patients, because the CUMS model recapitulates major features of
sporadic AD with an increased hippocampal content of hyperpho-
sphorylated PHF tau and an enhanced amyloid-beta (Abeta) generation
[33,122,123]. The Alzheimer-like and/or AD-aggravating phenotype
induced by CUMS is linked to advanced age because this phenotype
only develops in aged 15-month-old rats and aged Tg2576 AD mice
whereas young rats are not sensitive to the CUMS protocol
[33,124–126]. Moreover, we found that ACE is causally involved in
these AD-like neuropathologic features, which can be prevented by ACE
inhibition [33]. Consequently, the CUMS model can be considered as a
non-transgenic model of early sporadic AD [122]. Findings with the
CUMS model could thus be relevant to the pathogenesis of AD in pa-
tients because the CUMS model mimics stress as a major risk factor for
AD [127,128].
In addition to stress, advanced age is another factor, which could
contribute to a higher activity of the ACE-AT1 receptor axis in a typical
aging disease such as Alzheimer`s disease [129–131]. Aging-induced
sensitization of the detrimental ACE-AT1 receptor axis could in part be
mediated by down-regulation of the beneficial ACE2 and AT2 receptor
[130]. Taken together, stress in synergy with advanced age could be a
common inducer of ACE in brains of experimental AD models and AD
patients (Fig. 4).
6. ACE inhibition retards symptoms of neurodegeneration in
Tg2576 mice as a model of FAD
We established the causal involvement of ACE in neurodegeneration
and AD symptoms in the experimental Tg2576 AD model by treatment
with the brain-penetrating ACE inhibitor, captopril. Tg2576 AD mice
develop hippocampal Abeta plaques beginning at an age of 12 months
as a consequence of neuronal-specific expression of the APPSwe mu-
tant, which was identified in a Swedish family with early-onset familial
Alzheimer`s disease, FAD [8]. Tg2576 AD mice were treated for 6
months with captopril, starting at an age of 12 months. Hippocampal
whole genome microarray gene expression profiling demonstrated that
ACE inhibition induced a neuro-regenerative gene expression signature
and prevented the AD-related decreases in transcript levels of 38 hip-
pocampal genes with established functions in neuronal regeneration
and cognition [32]. Captopril not only retarded the AD-related neuro-
degeneration, but also actively promoted hippocampal neuro-re-
generation. Active neuro-regeneration by captopril was documented by
up-regulation of transcript levels of 12 hippocampal genes encoding
neuronal structure-forming proteins above the levels of the young
control group [32]. Notably, ACE inhibition “actively” triggered the
expression of hippocampal neuronal genes, which are known to be
defective in AD models and AD patients [32], such as the ephrin type-A
receptor 4, Epha4 [34], the sodium channel protein type 1 subunit
alpha, Scn1a [132], and the potassium voltage-gated channel subfamily
C member 1, Kcnc1 [133]. Concomitantly, ACE inhibition with capto-
pril led to the regeneration of neuronal processes of hippocampal CA1
neurons, which are degenerated in AD mice [32]. In addition, hippo-
campal Abeta plaque load was significantly reduced in 18-month-old
Tg2576 AD mice after 6 months of ACE inhibition compared to un-
treated age-matched Tg2576 controls [32].
These findings are complemented by other studies, which also
showed that central ACE inhibition retards symptoms of neurodegen-
eration, reduces Abeta accumulation and improves cognition in ex-
perimental models of AD [32,58–60]. The underlying neuroprotective
mechanism could involve the reduced generation of reactive oxygen
species, which is triggered by AT1 receptor activation [32]. Other ex-
perimental data confirm that central ACE inhibition-mediated neuro-
protection can be attributed to attenuation of oxidative stress and
downregulation of extracellular superoxide dismutase [35]. In addition,
ACE inhibition could retard brain aging by suppression of pathologic
pro-inflammatory astroglial activation mediated by angiotensin II AT1
receptor activation [35,134,135]. The CUMS model with early symp-
toms of early sporadic AD delineated that ACE inhibition dampens
glutamate excitotoxicity and mediates a decrease in hippocampal PHF
tau hyperphosphorylation (Fig. 4; [33]). Additional neuroprotective
activities of ACE inhibition are conceivable, e.g. those mediated by an
increased availability of bradykinin, which could exert neuroprotection
by stimulation of the bradykinin B2 receptor [136]. Although, further
studies are needed to address this possibility. Apart from bradykinin,
ACE inhibition also promotes the accumulation of angiotensin 1–7
(Fig. 1; and [52]), which could improve cerebral blood flow upon ac-
tivation of the AT1-inhibitory MAS1 and promote neuro-regeneration
by stimulation of the AT2 receptor [50,51,137].
Taken together, treatment with a centrally acting ACE inhibitor
retarded the development of major AD-related neuropathologic features
in the hippocampus of experimental models of FAD and sporadic AD,
i.e. tau hyperphosphorylation, glutamate excitotoxicity and Abeta ac-
cumulation [32,33]. These neuroprotective effects of centrally active
ACE inhibitors could be attributed to inhibition of angiotensin II AT1
receptor activation, because angiotensin II-induced AT1 receptor acti-
vation is known to promote PHF tau hyperphosphorylation and en-
hance glutamate excitotoxicity in vivo [138–140]. AT1-inhibitory
Fig. 4. Schematic representation of a vicious neurodegenerative circle triggered
by ACE-dependent angiotensin II AT1 receptor activation (modified from [32]).
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effects of ACE inhibitors could finally account for a decrease in Abeta
accumulation because the synergistic interplay between AT1 receptor-
mediated ROS generation [32,35], AT1 receptor-triggered PHF tau
phosphorylation and glutamate excitotoxicity enhances Abeta-genera-
tion by increased activation of Abeta-generating beta- and gamma-se-
cretases (Fig. 4; and [141–143]).
From our data, a vicious circle was deduced, which consists of ACE-
mediated angiotensin II generation and ensuing activation of the neu-
rodegenerative and Abeta-enhancing AT1 receptor (Fig. 4).
7. ACE inhibition retards symptoms of neurodegeneration in the
chronic unpredictable mild stress (CUMS) model, which
recapitulates features of sporadic AD
The Tg2576 AD model and other genetic AD models with transgenic
expression of mutated APP variants isolated from FAD patients re-
capitulate major features of early-onset, familial Alzheimer`s Disease,
FAD [8,9]. In contrast to FAD with inherited gene mutations, which
ultimately cause the disease, AD-causing genetic changes usually do not
occur in patients with late-onset sporadic AD, which affects more than
95% of all AD patients [144–146]. Therefore, we searched for a non-
genetic model of AD and applied the chronic unpredictable mild stress
(CUMS) model to reproduce features of sporadic AD [33]. Four weeks of
chronic unpredictable mild stress induced major features of sporadic
AD such as an increased hippocampal content of hyperphosphorylated
PHF tau and the enhanced generation of Abeta [33]. This neurode-
generative phenotype is only observed in aged rats at an age of 15
months, whereas young rats are insensitive to stress and do not develop
these features of neurodegeneration [33,124]. Thus, the CUMS model
develops an ageing-dependent phenotype of neurodegeneration, which
closely resembles the late-onset sporadic form of AD, for which age is
the best-established risk factor [1,147].
When we applied the CUMS model with features of sporadic AD, we
found that CUMS up-regulated the hippocampal ACE protein and ACE
activity in aged rats [33]. Concomitantly, chronic unpredictable mild
stress induced a neurodegenerative hippocampal gene expression sig-
nature, which was documented by the down-regulation of microtubule-
associated protein, MAP2, and synuclein gamma [33]. In addition,
glutamate excitotoxicity was enhanced by stress as evidenced by a
decrease in glutamate decarboxylase activity, and down-regulation of
the inhibitory NMDA receptor subtype, Grin3a [33], which is neuro-
protective and could counteract glutamate excitotoxicity [148,149].
The up-regulated ACE level contributed to this neurodegenerative
process because captopril prevented these symptoms of neurodegen-
eration [33].
Despite Abeta plaque load, most genetic AD models do not develop
overt neuronal loss, which is the major hallmark of AD in patients. To
enhance the process of neurodegeneration, we subjected aged Tg2576
AD mice to the CUMS protocol [125,126]. Chronic mild stress increased
the hippocampal content of hyperphosphorylated PHF tau in aged
Tg2576 AD mice [125]. Concomitantly, aged Tg2576 AD mice sub-
jected to CUMS, showed a significant neuronal loss in the hippocampal
CA1 region [125]. This finding is relevant to the human disease, be-
cause neuronal loss in the hippocampal CA1 region occurs early in AD
progression and accounts for major symptoms of dementia [150,151].
Taken together, we found a causal relationship between increased
ACE-dependent generation of angiotensin II, and the development of
major AD symptoms (Fig. 4). A hypersensitive HPA axis with increased
vulnerability to stress was identified as trigger for neuronal ACE in
experimental AD models (Fig. 4). Because an increased sensitivity to-
wards psychosocial stress is also an established risk factor of AD in
patients [127,128], our data from experimental models of FAD and
sporadic AD could be of major relevance for the human disease.
8. Translation of our findings from experimental models into
clinical practice
The relevance of our findings for AD patients is currently under
investigation. Several clinical data already have shown that inhibition
of ACE retards the process of neurodegeneration leading to dementia
and the incidence of AD [111–116,152]. Data from clinical practice
confirm that the neuroprotective activity is linked to centrally acting
ACE inhibitors [111–116,152]. The effect of central ACE inhibition
leads to reduced activation of the AT1 receptor; in fact, the neuropro-
tective effects of centrally acting AT1 receptor antagonists appear to be
even stronger [112]. A recent study determined the treatment effect of
centrally acting ACE inhibitors as add-on therapy to an acet-
ylcholinesterase inhibitor in AD patients. Outcome data of this study
show that a centrally acting ACE inhibitor could improve AD dementia
symptoms for about 9 months after diagnosis of AD, compared to the
treatment with a non-centrally acting ACE inhibitor, which led to a
deterioration of cognitive function [116]. This is a remarkable success
considering that the last drug approval for AD, i.e. memantine, was
about 15 years ago. Although, ACE inhibitors do not cure AD, the sig-
nificant improvement of symptoms of dementia with these within 9
months is a much better outcome compared to the one with Abeta-
targeting approaches in phase III clinical trials, which did not find any
measurable effect on AD symptoms [15–22]. A recent overview of all
clinical trials of amyloid-beta-targeting therapies for Alzheimer disease
supports this conclusion [153]. Even if there are still Abeta-targeting
drug candidates with apparently promising results in early stages of
clinical development, the failure of all amyloid-beta-targeting com-
pounds in large clinical trials during the past 20 years does not leave
much room for expectations to achieve substantial clinical benefit with
the amyloid-beta-targeting approach in the future [153]. Instead, ef-
forts could be redirected to interfere with modifiable risk factors, as it is
achieved, e.g. by ACE inhibitors and AT1 receptors antagonists, which
target virtually all major risk factors of AD. Consequently, centrally
acting ACE inhibitors (captopril, fosinopril, lisinopril, perindopril, ra-
mipril, trandolapril) and/or AT1 receptor antagonists could be con-
sidered for prevention of neurodegeneration and dementia in patients
at risk [36,116]. Finally, the neuroprotective targets discovered by our
studies with ACE inhibition, could be exploited to develop urgently
needed AD therapeutics in the near future.
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